Cargando…

Implantable Cardioverter‐Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and Complications

BACKGROUND: Arrhythmogenic right ventricular dysplasia/cardiomyopathy is characterized by ventricular arrhythmias and sudden cardiac death. Once the diagnosis is established, risk stratification to determine whether implantable cardioverter‐defibrillator (ICD) placement is warranted is critical. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Orgeron, Gabriela M., James, Cynthia A., Te Riele, Anneline, Tichnell, Crystal, Murray, Brittney, Bhonsale, Aditya, Kamel, Ihab R., Zimmerman, Stephan L., Judge, Daniel P., Crosson, Jane, Tandri, Harikrishna, Calkins, Hugh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669204/
https://www.ncbi.nlm.nih.gov/pubmed/28588093
http://dx.doi.org/10.1161/JAHA.117.006242
_version_ 1783275815456210944
author Orgeron, Gabriela M.
James, Cynthia A.
Te Riele, Anneline
Tichnell, Crystal
Murray, Brittney
Bhonsale, Aditya
Kamel, Ihab R.
Zimmerman, Stephan L.
Judge, Daniel P.
Crosson, Jane
Tandri, Harikrishna
Calkins, Hugh
author_facet Orgeron, Gabriela M.
James, Cynthia A.
Te Riele, Anneline
Tichnell, Crystal
Murray, Brittney
Bhonsale, Aditya
Kamel, Ihab R.
Zimmerman, Stephan L.
Judge, Daniel P.
Crosson, Jane
Tandri, Harikrishna
Calkins, Hugh
author_sort Orgeron, Gabriela M.
collection PubMed
description BACKGROUND: Arrhythmogenic right ventricular dysplasia/cardiomyopathy is characterized by ventricular arrhythmias and sudden cardiac death. Once the diagnosis is established, risk stratification to determine whether implantable cardioverter‐defibrillator (ICD) placement is warranted is critical. METHODS AND RESULTS: The cohort included 312 patients (163 men, age at presentation 33.6±13.9 years) with definite arrhythmogenic right ventricular dysplasia/cardiomyopathy who received an ICD. Over 8.8±7.33 years, 186 participants (60%) had appropriate ICD therapy and 58 (19%) had an intervention for ventricular fibrillation/flutter. Ventricular tachycardia at presentation (hazard ratio [HR]: 1.86; 95% confidence interval [CI], 1.38–2.49; P<0.001), inducibility on electrophysiology study (HR: 3.14; 95% CI, 1.95–5.05; P<0.001), male sex (HR: 1.62; 95% CI, 1.20–2.19; P=0.001), inverted T waves in ≥3 precordial leads (HR: 1.66; 95% CI, 1.09–2.52; P=0.018), and premature ventricular contraction count ≥1000/24 hours (HR: 2.30; 95% CI, 1.32–4.00; P=0.003) were predictors of any appropriate ICD therapy. Inducibility at electrophysiology study (HR: 2.28; 95% CI, 1.10–4.70; P=0.025) remained as the only predictor after multivariable analysis. The predictors for ventricular fibrillation/flutter were premature ventricular contraction ≥1000/24 hours (HR: 4.39; 95% CI, 1.32–14.61; P=0.016), syncope (HR: 1.85; 95% CI, 1.10–3.11; P=0.021), aged ≤30 years at presentation (HR: 1.76; 95% CI, 1.04–3.00; P<0.036), and male sex (HR: 1.73; 95% CI, 1.01–2.97; P=0.046). Younger age at presentation (HR: 3.14; 95% CI, 1.32–7.48; P=0.010) and high premature ventricular contraction burden (HR: 4.43; 95% CI, 1.35–14.57; P<0.014) remained as independent predictors of ventricular fibrillation/flutter. Complications occurred in 66 participants (21%), and 64 (21%) had inappropriate ICD interventions. Overall mortality was low at 2%, and 4% underwent heart transplantation. CONCLUSION: These findings represent an important step in identifying predictors of ICD therapy for potentially fatal ventricular fibrillation/flutter and should be considered when developing a risk stratification model for arrhythmogenic right ventricular dysplasia/cardiomyopathy.
format Online
Article
Text
id pubmed-5669204
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-56692042017-11-09 Implantable Cardioverter‐Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and Complications Orgeron, Gabriela M. James, Cynthia A. Te Riele, Anneline Tichnell, Crystal Murray, Brittney Bhonsale, Aditya Kamel, Ihab R. Zimmerman, Stephan L. Judge, Daniel P. Crosson, Jane Tandri, Harikrishna Calkins, Hugh J Am Heart Assoc Original Research BACKGROUND: Arrhythmogenic right ventricular dysplasia/cardiomyopathy is characterized by ventricular arrhythmias and sudden cardiac death. Once the diagnosis is established, risk stratification to determine whether implantable cardioverter‐defibrillator (ICD) placement is warranted is critical. METHODS AND RESULTS: The cohort included 312 patients (163 men, age at presentation 33.6±13.9 years) with definite arrhythmogenic right ventricular dysplasia/cardiomyopathy who received an ICD. Over 8.8±7.33 years, 186 participants (60%) had appropriate ICD therapy and 58 (19%) had an intervention for ventricular fibrillation/flutter. Ventricular tachycardia at presentation (hazard ratio [HR]: 1.86; 95% confidence interval [CI], 1.38–2.49; P<0.001), inducibility on electrophysiology study (HR: 3.14; 95% CI, 1.95–5.05; P<0.001), male sex (HR: 1.62; 95% CI, 1.20–2.19; P=0.001), inverted T waves in ≥3 precordial leads (HR: 1.66; 95% CI, 1.09–2.52; P=0.018), and premature ventricular contraction count ≥1000/24 hours (HR: 2.30; 95% CI, 1.32–4.00; P=0.003) were predictors of any appropriate ICD therapy. Inducibility at electrophysiology study (HR: 2.28; 95% CI, 1.10–4.70; P=0.025) remained as the only predictor after multivariable analysis. The predictors for ventricular fibrillation/flutter were premature ventricular contraction ≥1000/24 hours (HR: 4.39; 95% CI, 1.32–14.61; P=0.016), syncope (HR: 1.85; 95% CI, 1.10–3.11; P=0.021), aged ≤30 years at presentation (HR: 1.76; 95% CI, 1.04–3.00; P<0.036), and male sex (HR: 1.73; 95% CI, 1.01–2.97; P=0.046). Younger age at presentation (HR: 3.14; 95% CI, 1.32–7.48; P=0.010) and high premature ventricular contraction burden (HR: 4.43; 95% CI, 1.35–14.57; P<0.014) remained as independent predictors of ventricular fibrillation/flutter. Complications occurred in 66 participants (21%), and 64 (21%) had inappropriate ICD interventions. Overall mortality was low at 2%, and 4% underwent heart transplantation. CONCLUSION: These findings represent an important step in identifying predictors of ICD therapy for potentially fatal ventricular fibrillation/flutter and should be considered when developing a risk stratification model for arrhythmogenic right ventricular dysplasia/cardiomyopathy. John Wiley and Sons Inc. 2017-06-06 /pmc/articles/PMC5669204/ /pubmed/28588093 http://dx.doi.org/10.1161/JAHA.117.006242 Text en © 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research
Orgeron, Gabriela M.
James, Cynthia A.
Te Riele, Anneline
Tichnell, Crystal
Murray, Brittney
Bhonsale, Aditya
Kamel, Ihab R.
Zimmerman, Stephan L.
Judge, Daniel P.
Crosson, Jane
Tandri, Harikrishna
Calkins, Hugh
Implantable Cardioverter‐Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and Complications
title Implantable Cardioverter‐Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and Complications
title_full Implantable Cardioverter‐Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and Complications
title_fullStr Implantable Cardioverter‐Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and Complications
title_full_unstemmed Implantable Cardioverter‐Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and Complications
title_short Implantable Cardioverter‐Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and Complications
title_sort implantable cardioverter‐defibrillator therapy in arrhythmogenic right ventricular dysplasia/cardiomyopathy: predictors of appropriate therapy, outcomes, and complications
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669204/
https://www.ncbi.nlm.nih.gov/pubmed/28588093
http://dx.doi.org/10.1161/JAHA.117.006242
work_keys_str_mv AT orgerongabrielam implantablecardioverterdefibrillatortherapyinarrhythmogenicrightventriculardysplasiacardiomyopathypredictorsofappropriatetherapyoutcomesandcomplications
AT jamescynthiaa implantablecardioverterdefibrillatortherapyinarrhythmogenicrightventriculardysplasiacardiomyopathypredictorsofappropriatetherapyoutcomesandcomplications
AT terieleanneline implantablecardioverterdefibrillatortherapyinarrhythmogenicrightventriculardysplasiacardiomyopathypredictorsofappropriatetherapyoutcomesandcomplications
AT tichnellcrystal implantablecardioverterdefibrillatortherapyinarrhythmogenicrightventriculardysplasiacardiomyopathypredictorsofappropriatetherapyoutcomesandcomplications
AT murraybrittney implantablecardioverterdefibrillatortherapyinarrhythmogenicrightventriculardysplasiacardiomyopathypredictorsofappropriatetherapyoutcomesandcomplications
AT bhonsaleaditya implantablecardioverterdefibrillatortherapyinarrhythmogenicrightventriculardysplasiacardiomyopathypredictorsofappropriatetherapyoutcomesandcomplications
AT kamelihabr implantablecardioverterdefibrillatortherapyinarrhythmogenicrightventriculardysplasiacardiomyopathypredictorsofappropriatetherapyoutcomesandcomplications
AT zimmermanstephanl implantablecardioverterdefibrillatortherapyinarrhythmogenicrightventriculardysplasiacardiomyopathypredictorsofappropriatetherapyoutcomesandcomplications
AT judgedanielp implantablecardioverterdefibrillatortherapyinarrhythmogenicrightventriculardysplasiacardiomyopathypredictorsofappropriatetherapyoutcomesandcomplications
AT crossonjane implantablecardioverterdefibrillatortherapyinarrhythmogenicrightventriculardysplasiacardiomyopathypredictorsofappropriatetherapyoutcomesandcomplications
AT tandriharikrishna implantablecardioverterdefibrillatortherapyinarrhythmogenicrightventriculardysplasiacardiomyopathypredictorsofappropriatetherapyoutcomesandcomplications
AT calkinshugh implantablecardioverterdefibrillatortherapyinarrhythmogenicrightventriculardysplasiacardiomyopathypredictorsofappropriatetherapyoutcomesandcomplications